APY Therapeutics

APY Therapeutics LLC is developing arylmyxopyronins–APYs–as novel first-in-class oral treatments for lower-respiratory-tract infections and skin-and-soft-tissue infections caused by Gram-positive and fastidious Gram-negative bacteria, including drug-resistant, multi-drug-resistant, and pan-drug-resistant isolates.